Ignite Creation Date:
2024-05-06 @ 7:25 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06007651
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2023-08-18
Brief Title:
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease NAFLD
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 1 Multicenter Randomized Placebo-Controlled Double-Blind Trial of LY3885125 to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of a Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With NAFLD
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia part A and multiple doses in participants with non-alcoholic fatty liver disease part B Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it
The study will last up to approximately 49 weeks for part A and 62 weeks for part B for a total of approximately 111 weeks
The study will last up to approximately 49 weeks for part A and 62 weeks for part B for a total of approximately 111 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J4N-MC-YFAA | OTHER | Eli Lilly and Company | None |